Novel Platforms for the Development of a Universal influenza vaccine

Arun Kumar, Trine Sundebo Meldgaard, Sylvie Bertholet*

*Corresponding author for this work

    Research output: Contribution to journalJournal articleResearchpeer-review

    214 Downloads (Pure)

    Abstract

    Despite advancements in immunotherapeutic approaches, influenza continues to cause severe illness, particularly among immunocompromised individuals, young children, and elderly adults. Vaccination is the most effective way to reduce rates of morbidity and mortality caused by influenza viruses. Frequent genetic shift and drift among influenzavirus strains with the resultant disparity between circulating and vaccine virus strains limits the effectiveness of the available conventional influenza vaccines. One approach to overcome this limitation is to develop a universal influenza vaccine that could provide protection against all subtypes of influenza viruses. Moreover, the development of a novel or improved universal influenza vaccines may be greatly facilitated by new technologies including virus-like particles, T-cell-inducing peptides and recombinant proteins, synthetic viruses, broadly neutralizing antibodies, and nucleic acid-based vaccines. This review discusses recent scientific advances in the development of next-generation universal influenza vaccines.
    Original languageEnglish
    Article number600
    JournalFrontiers in Immunology
    Volume9
    Number of pages14
    ISSN1664-3224
    DOIs
    Publication statusPublished - 2018

    Keywords

    • Influenza
    • Hemagglutinin
    • Virus-like particles
    • Universal flu vaccine
    • Neutralizing antibodies
    • Vaccination strategies
    • Functional antibody responses

    Cite this

    @article{89ecfc904e2c4f3e80c32853873c9f85,
    title = "Novel Platforms for the Development of a Universal influenza vaccine",
    abstract = "Despite advancements in immunotherapeutic approaches, influenza continues to cause severe illness, particularly among immunocompromised individuals, young children, and elderly adults. Vaccination is the most effective way to reduce rates of morbidity and mortality caused by influenza viruses. Frequent genetic shift and drift among influenzavirus strains with the resultant disparity between circulating and vaccine virus strains limits the effectiveness of the available conventional influenza vaccines. One approach to overcome this limitation is to develop a universal influenza vaccine that could provide protection against all subtypes of influenza viruses. Moreover, the development of a novel or improved universal influenza vaccines may be greatly facilitated by new technologies including virus-like particles, T-cell-inducing peptides and recombinant proteins, synthetic viruses, broadly neutralizing antibodies, and nucleic acid-based vaccines. This review discusses recent scientific advances in the development of next-generation universal influenza vaccines.",
    keywords = "Influenza, Hemagglutinin, Virus-like particles, Universal flu vaccine, Neutralizing antibodies, Vaccination strategies, Functional antibody responses",
    author = "Arun Kumar and Meldgaard, {Trine Sundebo} and Sylvie Bertholet",
    year = "2018",
    doi = "10.3389/fimmu.2018.00600",
    language = "English",
    volume = "9",
    journal = "Frontiers in Immunology",
    issn = "1664-3224",
    publisher = "Frontiers Research Foundation",

    }

    Novel Platforms for the Development of a Universal influenza vaccine. / Kumar, Arun; Meldgaard, Trine Sundebo; Bertholet, Sylvie.

    In: Frontiers in Immunology, Vol. 9, 600, 2018.

    Research output: Contribution to journalJournal articleResearchpeer-review

    TY - JOUR

    T1 - Novel Platforms for the Development of a Universal influenza vaccine

    AU - Kumar, Arun

    AU - Meldgaard, Trine Sundebo

    AU - Bertholet, Sylvie

    PY - 2018

    Y1 - 2018

    N2 - Despite advancements in immunotherapeutic approaches, influenza continues to cause severe illness, particularly among immunocompromised individuals, young children, and elderly adults. Vaccination is the most effective way to reduce rates of morbidity and mortality caused by influenza viruses. Frequent genetic shift and drift among influenzavirus strains with the resultant disparity between circulating and vaccine virus strains limits the effectiveness of the available conventional influenza vaccines. One approach to overcome this limitation is to develop a universal influenza vaccine that could provide protection against all subtypes of influenza viruses. Moreover, the development of a novel or improved universal influenza vaccines may be greatly facilitated by new technologies including virus-like particles, T-cell-inducing peptides and recombinant proteins, synthetic viruses, broadly neutralizing antibodies, and nucleic acid-based vaccines. This review discusses recent scientific advances in the development of next-generation universal influenza vaccines.

    AB - Despite advancements in immunotherapeutic approaches, influenza continues to cause severe illness, particularly among immunocompromised individuals, young children, and elderly adults. Vaccination is the most effective way to reduce rates of morbidity and mortality caused by influenza viruses. Frequent genetic shift and drift among influenzavirus strains with the resultant disparity between circulating and vaccine virus strains limits the effectiveness of the available conventional influenza vaccines. One approach to overcome this limitation is to develop a universal influenza vaccine that could provide protection against all subtypes of influenza viruses. Moreover, the development of a novel or improved universal influenza vaccines may be greatly facilitated by new technologies including virus-like particles, T-cell-inducing peptides and recombinant proteins, synthetic viruses, broadly neutralizing antibodies, and nucleic acid-based vaccines. This review discusses recent scientific advances in the development of next-generation universal influenza vaccines.

    KW - Influenza

    KW - Hemagglutinin

    KW - Virus-like particles

    KW - Universal flu vaccine

    KW - Neutralizing antibodies

    KW - Vaccination strategies

    KW - Functional antibody responses

    U2 - 10.3389/fimmu.2018.00600

    DO - 10.3389/fimmu.2018.00600

    M3 - Journal article

    C2 - 29628926

    VL - 9

    JO - Frontiers in Immunology

    JF - Frontiers in Immunology

    SN - 1664-3224

    M1 - 600

    ER -